Free Trial

Eurofins (ERFFP: Baa3 / BBB-): Conference call

HEALTHCARE
  • All sounded very positive.
  • Margins are growing - now above 20% - with aim to get to 24%.
  • IT spend is 6% of revenue which is twice what they would like it to be. They are currently investing a lot in tech to make a more modern/efficient business. After this investment, margins will mechanically improve because of lower spending but also should see organic growth.
  • Dr Martin addressed the problem of his property holdings by saying that the buildings will be offered for sale to the company if other shareholders wish it.
  • The rents involved are tiny compared to the overall spend of the company - Dr Martin acknowledges the optics of the situation but thinks it's meaningless in terms of the financials of the company.
  • The company is buying back its shares - limited disclosure of size - as they think they are too cheap.
  • Growth areas are AI tools to offer value added tools to pharma for drug development. They also have their own direct to healthcare product development such as Genome-Wide Non-Invasive Prenatal Tests
  • Will continue to invest and make small acquisitions. ROCE target 16+%
  • Results of Cash Audit will be in autumn. Giving them full access.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.